• 1
    Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 9326.
  • 2
    Alghisi GC, Rüegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006; 13: 11335.
  • 3
    Varner JA, Brooks PC, Cheresh DA. Review: the integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun 1995; 3: 36774.
  • 4
    Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 64715.
  • 5
    Malik RK. Regulation of apoptosis by integrin receptors. J Pediatr Hematol Oncol 1997; 19: 5415.
  • 6
    Scatena M, Almeida M, Chaisson ML, et al. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 108393.
  • 7
    Brooks PC, Strömblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 181522.
  • 8
    Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 115764.
  • 9
    Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 56971.
  • 10
    Mitjans F, Sander D, Adán J, et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108: 282538.
  • 11
    Smith JW, Vestal DJ, Irwin SV, et al. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J Biol Chem 1990; 265: 1100813.
  • 12
    Charo IF, Nannizzi L, Smith JW, et al. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol 1990; 111: 2795800.
  • 13
    Smith JW, Cheresh DA. Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem 1990; 265: 216872.
  • 14
    Cheng YF, Clyman RI, Enenstein J, et al. The integrin complex alpha v beta 3 participates in the adhesion of microvascular endothelial cells to fibronectin. Exp Cell Res 1991; 194: 6977.
  • 15
    Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 147582.
  • 16
    Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 1515.
  • 17
    Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003:39: 91726.
  • 18
    Dechantsreiter MA, Planker E, Mathä B, et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999: 42: 303340.
  • 19
    Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010; 10: 75368.
  • 20
    Alghisi GC, Ponsonnet L, Rüegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009; 4: e4449.
  • 21
    Nisato RE, Tille JC, Jonczyk A, et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6: 10519.
  • 22
    Buerkle MA, Pahernik SA, Sutter A, et al. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86: 78895.
  • 23
    MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 1517.
  • 24
    Burke PA, DeNardo SJ, Miers LA, et al. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002; 94: 132031.
  • 25
    Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124: 271927.
  • 26
    Burke PA, DeNardo SJ, Miers LA, et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62: 426372.
  • 27
    Bretschi M, Merz M, Komljenovic D, et al. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 2011; 26: 84351.
  • 28
    Bäuerle T, Komljenovic D, Merz M, et al. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011; 128: 245362.
  • 29
    Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4: 42937.
  • 30
    de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 10003.
  • 31
    Seynhaeve AL, Vermeulen CE, Eggermont AM, et al. Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells. Cell Biochem Biophys 2006; 44: 15769.
  • 32
    van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82: 97380.
  • 33
    Vermorken JB, Guigay J, Mesia R, et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 2011; 104: 16916.
  • 34
    Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 271218.
  • 35
    Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 922.
  • 36
    Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 561017.
  • 37
    de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80: 1616.
  • 38
    Brunstein F, Hoving S, Seynhaeve AL, et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004; 96: 160310.
  • 39
    Tjaden UR, de Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr 1990; 531: 23594.
  • 40
    Goodman SL, Aumailley M, von der Mark H. Multiple cell surface receptors for the short arms of laminin: alpha 1 beta 1 integrin and RGD-dependent proteins mediate cell attachment only to domains III in murine tumor laminin. J Cell Biol 1991; 113: 93141.
  • 41
    Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 274556.
  • 42
    Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 110712.
  • 43
    Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 3204.
  • 44
    Cheresh DA. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev 1991; 10: 310.
  • 45
    Seftor RE, Seftor EA, Gehlsen KR, et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 155761.
  • 46
    Panetti TS, McKeown-Longo PJ. The alpha v beta 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 16: 114925.
  • 47
    Felding-Habermann B, Mueller BM, Romerdahl CA, et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 201822.
  • 48
    Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 30919.
  • 49
    Nabors LB, Mikkelsen T, Hegi ME, et al.; for the New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118: 56015607.
  • 50
    Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25: 16517.